JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms by Mar Bellido, Peter A. W. te Boekhorst

Get full text

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial by Carsten U. Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H.M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Wida Razawy, René Hollestein, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Arnon P. Kater, Mark-David Levin

Get full text